Results from BILAP, a 5-year study on survival data conducted at the UCL Cancer Institute in London, U.L. confirmed "the benefit of capecitabine as adjuvant therapy after surgical resection of biliary tract cancer...and should be considered as the standard of care." Conducted between March 15 2006 - December 4, 2014 on 447 patients (of whom 223 were assigned to the capecitabine group for curative intent), indicated a period of 24.3 months for median recurrence-free survival for patients prescribed capecitabine compared to 17.4 months for those in the observation group.
To read more about the BILAP study, click here.
Source mentioned: Bridgewater J, Fletcher P, Palmer DH, et al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. Journal of Clinical Oncology; Published online 22 March 2022. DOI: 10.1200/JCO.21.02568
No comments:
Post a Comment